Avaliação das estruturas químicas derivadas de diaminas do ferroceno no metabolismo oxidativo em cepas de Trypanosoma cruzi
Data
2013-07-11
Autores
Kohatsu, Andréa Akiko Nakaima [UNESP]
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Estadual Paulista (Unesp)
Resumo
No momento há apenas dois fármacos disponíveis para o tratamento da doença de Chagas, nifurtimox e benzonidazol, ambos de ações limitadas. Assim, a compreensão dos mecanismos utilizados por T. cruzi para diminuir os efeitos citotóxicos de fármacos e a busca de potenciais moléculas para quimioterapia, bem como os alvos para elas, são de extrema importância. O aumento na produção de certas enzimas do metabolismo oxidativo seria responsável pela resistência das cepas do parasito ao benzonidazol (BZ). Tais enzimas são: triparedoxina peroxidase (mTcTXNPx) que catalisa a redução de peróxidos, superóxido dismutase (mTcSOD) que realiza a dismutação do ânion superóxido e old yellow enzyme (cTcOYE) que está envolvida na redução de substâncias tripanossomicidas, como naftoquinonas e compostos nitroheterocíclicos. Estudos demonstram que a atividade antimalarial da cloroquina foi aumentada com a adição de ferroceno. Neste trabalho, foram avaliadas as diferenças de suscetibilidade entre seis cepas de T. cruzi (Y, Bolívia, SI1, SIGR3, SI8 e QMII) em relação a três estruturas derivadas de diaminas do ferroceno e a expressão das proteínas antioxidativas. A substância AAC09 mostrou maior citotoxicidade, com CI50 de 2,21 μM para a cepa menos resistente (cepa Y) e 15,20 μM (cepa QMII) para a mais resistente, enquanto que para BZ foi 27,28 μM (cepa SI1) e 105,28 μM (cepa SIGR3), respectivamente. Após tratamento, a expressão das enzimas mTcTXNP (25,5 kDa) e cTcOYE (43 kDa) não aumentaram em cepas mais resistentes aos derivados de diaminas do ferroceno e BZ. Por outro lado, somente ocorreu aumento de expressão de mTcTXNPx na cepa Y tratada com BZ. Os resultados obtidos mostraram que cada cepa apresenta distinta suscetibilidade a um agente oxidativo e as cepas mais resistentes não aumentaram a expressão das...
At the moment there are only two drugs available for the treatment of Chagas disease, nifurtimox and benznidazole, both of use restricted. Understanding the mechanisms used by T. cruzi to reduce de cytotoxic effects of drugs and finding potential molecules for chemotherapy, as well as targets for them, are extremely important. Resistance to benznidazole (BZ) in T. cruzi strains may be caused by increased production of enzymes that act on oxidative metabolism. Such enzymes are: tryparedoxin peroxidase (mTcTXNPx), which catalyzes the reduction of peroxides, superoxide dismutase (mTcSOD), which performs the dismutation of superoxide anion and old yellow enzyme (cTcOYE), which is related to the reduction of trypanocidal substances, such as naphthoquinones and nitroheterocyclic compounds. Studies showed that the antimalarial activity of chloroquine was increased with the addition of ferroceno. Herein the susceptibilities in six T. cruzi strains (Y, Bolivia, SI1, SIGR3, SI8 and QMII) were analyzed in relation to three structures of ferrocene diamine derivatives and the expression of antioxidant proteins. The AAC09 substance showed higher cytotoxicity, with IC50 of 2.21 μM for the less resistant strain (Y strain) and 15.20 μM (QMII strain) for more resistant, whereas to BZ was 27.28 μM (strain SI1) and 105.28 μM (SIGR3), respectively. After treatment, the expression of the enzymes mTcTXNP (25.5 kDa) and cTcOYE (43 kDa) did not increase in more resistant strains to ferrocene diamine derivatives and BZ. However, there was increased expression of mTcTXNPx only in the Y strain treated with BZ. The results showed that each strain exhibited different susceptibility to oxidative agent and the most resistant strains did not enhance expression of these enzymes. Based on these findings, probably other mechanisms may be... (Complete abstract click electronic access below)
At the moment there are only two drugs available for the treatment of Chagas disease, nifurtimox and benznidazole, both of use restricted. Understanding the mechanisms used by T. cruzi to reduce de cytotoxic effects of drugs and finding potential molecules for chemotherapy, as well as targets for them, are extremely important. Resistance to benznidazole (BZ) in T. cruzi strains may be caused by increased production of enzymes that act on oxidative metabolism. Such enzymes are: tryparedoxin peroxidase (mTcTXNPx), which catalyzes the reduction of peroxides, superoxide dismutase (mTcSOD), which performs the dismutation of superoxide anion and old yellow enzyme (cTcOYE), which is related to the reduction of trypanocidal substances, such as naphthoquinones and nitroheterocyclic compounds. Studies showed that the antimalarial activity of chloroquine was increased with the addition of ferroceno. Herein the susceptibilities in six T. cruzi strains (Y, Bolivia, SI1, SIGR3, SI8 and QMII) were analyzed in relation to three structures of ferrocene diamine derivatives and the expression of antioxidant proteins. The AAC09 substance showed higher cytotoxicity, with IC50 of 2.21 μM for the less resistant strain (Y strain) and 15.20 μM (QMII strain) for more resistant, whereas to BZ was 27.28 μM (strain SI1) and 105.28 μM (SIGR3), respectively. After treatment, the expression of the enzymes mTcTXNP (25.5 kDa) and cTcOYE (43 kDa) did not increase in more resistant strains to ferrocene diamine derivatives and BZ. However, there was increased expression of mTcTXNPx only in the Y strain treated with BZ. The results showed that each strain exhibited different susceptibility to oxidative agent and the most resistant strains did not enhance expression of these enzymes. Based on these findings, probably other mechanisms may be... (Complete abstract click electronic access below)
Descrição
Palavras-chave
Trypanosoma cruzi, Ferroceno, Proteínas, Antioxidantes, Peroxidase, Antioxidants
Como citar
KOHATSU, Andréa Akiko Nakaima. Avaliação das estruturas químicas derivadas de diaminas do ferroceno no metabolismo oxidativo em cepas de Trypanosoma cruzi. 2013. 88 f. Dissertação (mestrado) - Universidade Estadual Paulista Júlio de Mesquita Filho, Faculdade de Ciências Farmacêuticas de Araraquara, 2013.